Steadtrust LLC Acquires 1,197 Shares in Eli Lilly

The institutional investor added to its position in the pharmaceutical giant during Q4 2025.

Apr. 11, 2026 at 10:08am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of complex pharmaceutical manufacturing equipment, gears, and machinery in muted industrial tones, conceptually representing the behind-the-scenes operations that drive a major drug company's success.Institutional investors are closely monitoring Eli Lilly's manufacturing capabilities and supply chain as the pharmaceutical giant continues to attract new shareholders.Indianapolis Today

Steadtrust LLC, an institutional investor, acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter of 2025, according to a recent SEC filing. The firm purchased 1,197 shares of the company's stock, valued at approximately $1,286,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor changes in ownership of Lilly's stock, as it can signal broader market sentiment and investment trends in the healthcare sector.

The details

Steadtrust LLC's new position in Lilly adds to the company's growing institutional ownership, which currently stands at 82.53% of total shares outstanding. The filing indicates Steadtrust's investment strategy likely views Lilly as an attractive long-term holding given the firm's robust drug pipeline, global commercial footprint, and strong financial performance.

  • Steadtrust LLC acquired the 1,197 Lilly shares during the fourth quarter of 2025.

The players

Steadtrust LLC

An institutional investment firm that has acquired a new position in shares of Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, known for developing innovative medicines across a range of therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's stock continues to attract interest from major institutional investors like Steadtrust LLC, signaling confidence in the company's long-term growth prospects within the pharmaceutical industry.